Targacept.

PositionTriad - Clinical report

Winston-Salem drug developer Targacept plans to continue work on a potential Alzheimer's drug despite inconclusive results from a clinical trial. TC-1734 performed no better than a placebo in the 12-week study of 567 patients, the company says. Targacept believes the results would have been better had the trial lasted longer. The drug also is being...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT